drugset
Drugs / ras peptide cancer vaccine
last change May 2007 re-read 2 minutes ago

ras peptide cancer vaccine

Vaccine

Developed for
colorectal cancer · lung cancer · malignant pancreatic neoplasm · breast cancer · cervical cancer · cutaneous melanoma · endometrial cancer · head and neck cancer
+9 more · liver cancer · malignant colon neoplasm · myelodysplastic syndrome · non-small cell lung carcinoma · ovarian cancer · pancreas disorder · rectal carcinoma · small cell lung carcinoma · testicular germ cell tumor
Investigated by
National Cancer Institute (NCI) · Memorial Sloan Kettering Cancer Center · Fox Chase Cancer Center

Trials 7 · a red edge is where a trial was stopped

today NCT00006387 · Ph 1 NCT00005630 · Ph 1 NCT00003959 · Ph 1 NCT00019591 · Ph 1/2 NCT00019331 · Ph 2 NCT00019084 · Ph 2 NCT00019006 · Ph 1
199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 14 trials
Phase 1 NCT00006387 Oct 2000 → Jan 2002 colorectal cancer, malignant pancreatic neoplasm Fox Chase Cancer Center Completed No outcome recorded
Phase 1 NCT00005630 Jul 1999 → May 2002 lung cancer Memorial Sloan Kettering Cancer Center Completed No outcome recorded
Phase 1 NCT00003959 Jun 1999 → Dec 2001 leukemia, myelodysplastic syndrome Memorial Sloan Kettering Cancer Center Completed No outcome recorded
Phase 1 NCT00019006 Mar 1995 → ? malignant colon neoplasm, non-small cell lung carcinoma, pancreas disorder, rectal carcinoma +1 National Cancer Institute (NCI) Completed No outcome recorded
Phase 1/21 trial
Phase 1/2 NCT00019591 Mar 1999 → Nov 2005 colorectal cancer National Cancer Institute (NCI) Completed No outcome recorded
Phase 22 trials
Phase 2 NCT00019331 Oct 1997 → May 2007 colorectal cancer, cutaneous melanoma, endometrial cancer, head and neck cancer +4 National Cancer Institute (NCI) Completed No outcome recorded
Phase 2 NCT00019084 Feb 1996 → May 2003 breast cancer, cervical cancer, colorectal cancer, lung cancer +2 National Cancer Institute (NCI) Completed No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 7 sources stand behind the page.

FieldValueCited text
Known as ras peptide cancer vaccine ClinicalTrials.gov intervention name — accepted as the source's own label NCT00005630 ↗
6

NCT00006387 ↗

NCT00019006 ↗

NCT00019084 ↗

NCT00003959 ↗

NCT00019591 ↗

NCT00019331 ↗
Action Deplete “Vaccines may make the body build an immune response to kill tumor cells.” NCT00006387 ↗
Modality Vaccine “mutant N-, K-, or H-ras peptide vaccine” NCT00003959 ↗
Route Other “mutant K-ras peptide vaccine (limited to the specific K-ras mutation in their tumors) ID on day 7” NCT00005630 ↗